This study aims to carry out a multi-center, randomized controlled study on patients with recurrent ovarian cancer after PARPi maintenance, to explore the clinicopathological and molecular characteristics of patients with recurrent ovarian cancer after PARPi maintenance, and to clarify whether patients with recurrent ovarian cancer after PARPi maintenance for more than 6 months are sensitive to platinum drugs, and the value of secondary tumor cell reduction in such treatment, In order to provide evidence-based medicine basis for the standardized treatment mode of recurrent ovarian cancer after PARPi maintenance treatment.
Patients with diagnosis of first-line or second-line recurrent epithelial ovarian carcinoma, peritoneal carcinoma, or fallopian tube carcinoma, who has previously received at least 4 cycles of platinum-based chemotherapy in initial treatment;
Relapse occurred after 6 month since platinum-based chemotherapy;
PARPi maintenance therapy for more than 6 months before relapse;
R0 ideal debulking in initial surgery;
Platinum-refractory/uncontrolled epithelial ovarian cancer;
Non-epithelial ovarian tumor, mucinous, serous-mucinous (mainly mucinous), malignant Brenner tumor, low-grade serous carcinoma, borderline tumor;
Suffering from other malignant tumors that have not achieved complete remission in the past 2 years;
Received radiotherapy within 2 weeks before the start of the study intervention;
Parallel
Secondary cytoreduction
Procedure/SurgeryOpen surgery is conducted by senior clinicians in gynecological oncology. Operation time，location and number of relapsed lesions, location and number of excised lesions, Whether achieved R0 or not, and other information are recorded.
Chemotherapy
Drugchemotherapy
progression free survival (PFS)
progression free survival
Click on the lead sponsor to view all of their trials.
